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Introduction 
Recent legislative and regulatory activity designed to address controlled substance 
diversion and overuse of narcotics is having a significant impact on prescription drug 
utilization and patient care in the United States.  Although providers and patients are the 
focus of these new requirements, the designers and implementers of formularies and 
medication use protocols need to be aware of salient features of these initiatives.  
Formulary drug product selection, prior authorization procedures and drug utilization 
strategies should be reconsidered in accordance with the changes in controlled 
substance oversight. 
The primary focus of this article involves recent approaches to controlling the illegal 
acquisition of licit prescriptions, particularly opioid pain relievers (OPR). According to the 
Centers for Disease Control and Prevention (CDC), in 2008 OPRs were involved in 74% 
of the 20,000 fatal prescription drug overdoses in the United States.  This represents an 
increase of over 300% since 1999 and these fatalities now exceed death by cocaine 
and heroin combined. [1] Interestingly, the death rate varied five-fold by state, largely 
reflecting different levels of opioid regulation and oversight. They also noted that sales 
of OPRs quadrupled between 2000 and 2010 and that OPR abuse cost health insurers 
over $72 billion annually in healthcare costs. [2] 
 
Federal legislative and policy strategies 
The federal government controls the distribution and access to these dangerous and 
addictive drugs through the Controlled Substances Act (CSA) and the Food, Drug and 
Cosmetic Act (FDCA) as enforced by the Drug Enforcement Agency (DEA). The CSA 
regulates controlled prescription medication through a tiered system reflecting current 
accepted medical use of the substance and increased danger for abuse or misuse. [3] 
Formulary treatment of Schedule II through V varies considerably among ambulatory 
and institutional healthcare organizations.  The overuse and diversion of newer opioid 
preparations has led to considerable legislative and regulatory activity. 
 The Center for Medicare and Medicaid Services (CMS) has taken a lead in managing 
the overuse of opioids and acetaminophen in its beneficiary populations.  CMS created 
the Medicare Part D Overutilization Monitoring System (OMS) that uses claims data to 
identify individuals at risk.  CMS will use OMS to ensure plan sponsors’ drug utilization 
review (DUR) programs are effective in preventing overuse as required in 42 C.F.R 
§423.153 et seq. Their guidance offers methodology for identifying those outliers at risk 
for opioid and acetaminophen overutilization.  CMS will use the following identifying 
criteria to define outliers for overuse: 
1. Opioid outliers: Excluding patients with cancer or receiving hospice care, 
beneficiaries whose daily morphine equivalent dose (“MED”) is greater than 120 mg for 
at least 90 consecutive days, and who used more than 3 prescribers and more than 3 
pharmacies.  
2. Acetaminophen (APAP) outliers: Beneficiaries who may be taking more than 4 g of 
APAP per day for more than 30 days.  
 
3. Center for Program Integrity (CPI) referral outliers: Beneficiaries referred by the 
Medicare CPI for review of possible utilization issues. These referrals involve potential 
fraud or abuse of prescriptions in the Part D program and may include non-opioid 
cases.  
 
The OMS quarterly reports on overutilization will be available to sponsors through a web 
portal.  Sponsors are required to respond to CMS within 30 days as to the implemented 
initiatives to address each case.  Plan sponsors may include point-of-service (POS) 
edits in collaboration with prescribers for identified beneficiary.  However, if the 
prescriber is non-responsive to inquiries by the sponsor, the sponsor may proceed 
without collaboration. [4]  
During the current 113th United States Congress, approximately 75 bills have been 
submitted related to controlled substances.  The most viable of these legislative 
initiatives attempt to address narcotic diversion by encouraging the creation of national 
registries of controlled substance prescribing, limiting opioid selection by reclassifying 
certain narcotics to a higher or more regulated classification and enhancing controlled 
substance reporting and audit requirements at the federal level.  Some attempt to 
preserve liberal opioid prescribing protocols for terminally ill patients and those in 
intractable pain. [5] 
The pharmaceutical manufacturers have been under a great deal of pressure to assist 
in the overutilization of their products.  In January 2013, the Food and Drug 
Administration (FDA) drafted guidance for manufacturers on abuse-deterrent opioids, 
evaluation and labeling. [6] In November 2013 the FDA stated that it plans to request 
reclassification of hydrocodone combination products from Schedule III to Schedule II 
as early as December 2013.  These products are among the most prescribed pain 
medications in the country and among the most abused and diverted. [7] This 
scheduling change certainly may affect pain management protocols and formulary 
placement of hydrocodone products as the regulatory burden of prescribing 
hydrocodone increases. A possible unintended consequence of this action might 
include prescribing shifts to other opioids, including more expensive branded products.    
 
State policy strategies  
While the federal government has embarked on numerous controlled substances 
initiatives under its purview, individual states have attempted to address the problem in 
a variety of ways.  In February of this year, New York rescheduled hydrocodone 
combination products to CII thus tightening prescribing and eliminating refills.  More 
common amongst the states is the creation of prescription drug monitoring program 
known as PDMP or PMPs. A typical PMP collects all state-wide controlled substances 
prescription dispensing data at predetermined intervals and stores it in an electronic 
database that is available for DUR. The agency responsible for collecting the data 
would be authorized to share that information with other agencies or individuals so 
designated by state law. [8] As of July 2013, 47 states had operational PMPs while two 
were currently operationalizing their PMPs and one state had PMP legislation pending.  
In addition, 21 of these states are working with the National Boards of Pharmacy 
(NABP) to integrate their data into NABP’s PMP InterConnect that allows sharing of 
data.  [9] 
 States are using the information in their databases to varying degrees.  For example, 
Kentucky and New York require prescribers register for their PMPs and access the 
information before prescribing.  Kentucky’s prescribers must access the database 
before writing the initial prescription for controlled substances and throughout the 
patient’s treatment.  This diligence has seen Kentucky’s nonmedical use of prescription 
pain medication ranking drop from 2nd to 31st in the nation.[10]  In August 2013, New 
York required prescribers to register for PMP access as well as access the PMP before 
writing for control substances as part of their I-STOP, ACT 2012.[11]  Many states 
generate threshold reports that are sent to prescribers and pharmacists to review.  
Prescribers and pharmacists are requested to review these reports and discuss with 
other prescribers/pharmacists who will be responsible for patient care. 
 
Provider concerns related to legal exposure for failing to adhere to PMP regulations has 
prompted 26 states to specifically provide civil and/or criminal immunity to prescribers 
and dispensers. These statutes protect certain actions associated with accessing, failing 
to access, or reporting data to the prescription monitoring program database. [12] 
 
Currently, Wyoming and New York require real time submission of controlled 
substances claims to their PMP while Delaware, Kansas, Kentucky, Minnesota, North 
Dakota and West Virginia require reporting within 24 hours.  The remaining states vary 
in submission requirements up to 30 days. [12] 
 
This move toward state PMPs was fostered by several federal policy initiatives and 
funding opportunities.  The U.S. Department of Justice offers seed funding to plan, 
implement and enhance PMP efforts, while the Department of Health and Human 
Services administers a program to foster PMPs that meet consistent national criteria 
and allow for the interstate exchange of data. [11] There have been numerous federal 
legislative attempts to create a PMP on the national level.  [12] 
 
Discussion and Conclusion   
Pharmacy has been in the legislative and regulatory forefront on multiple issues in 2013 
including the continual battle to address prescription drug diversion. The Department of 
Justice, DEA, and other local law enforcement agencies have now gained new 
supporters as a result of the growing problem of legitimate controlled substance 
prescription diversion and overuse of narcotics across the U.S.  The consequences of 
this diversion include adverse societal, clinical and economic impacts. 
As a result of this high profile and recent legislative activity, Pharmacy and Therapeutics 
(P&T) committees need to discuss where this is leading to regarding assuring the 
provision of optimal patient care by their organization.  Pharmacy organizations are 
reporting compelling and revealing responses concerning controlled substances to treat 
acute or chronic pain such as:  
• Pharmacists turning away patients due to limits on monthly dispensing 
• Wholesaler inspections to assure appropriate dispensing or risk being denied 
drug orders by that supplier due to past DEA imposed record keeping fines (see 
call out at end of document) 
• Hesitancy by suppliers and other regulatory agencies to provide clear guidance 
that address many of the gray areas in real-world pharmacy dispensing 
situations.  
Again, questions are being asked about DEA’s position on this issue, and placing 
pharmacists in untenable roles that can conflict with their clinician responsibilities to 
patient care. 
Regardless of individual positions, the high potential for political consensus will continue 
to drive more action in this area by elected officials at all levels.  There is a prescription 
drug abuse problem in this country and legitimate patients are once again in danger of 
not having their medical pain needs met.  The conflict among regulatory and 
enforcement agencies at every levels fuels the continuing lack of resolution to the 
country’s drug abuse problem. This is evident in what we have seen with marijuana 
legislation; federal and state agencies are at odds with one another over its regulation 
as well as enforcement of legal justice. 
Health care entities such as hospitals, health systems, and managed care organizations 
must be engaged in this complicated yet locally driven issue. The consequences to the 
systems for ignoring this problem will be exacerbated under reimbursement rules that 
are gaining momentum under health care reform.  The direction of reform is to place the 
ultimate economic burden at the door of these health care entities.  Similar to never 
events and continuity of care initiatives, addressing community based health care 
issues can be an opportunity for health care entities employing effective population 
health efforts in local communities. The implementation and effect of various health 
policies around controlled substances remains uneven at best, but the opportunity for 
creating a better outcome can occur from grassroots efforts that begin with enlightened 
P&T members of these critically important health care entities. 
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DEA Record Keeping Fines 
 
Wifredo A. Ferrer, United States Attorney for the Southern District of Florida, and Mark R. 
Trouville, Special Agent in Charge, Drug Enforcement Administration (DEA), Miami Field 
Division, announced that Walgreens Corporation (Walgreens), the nation's largest drug store 
chain, has agreed to pay $80 million in civil penalties, resolving the DEA's administrative actions 
and the United States Attorney's Office's civil penalty investigation regarding the Walgreens 
Jupiter Distribution Center and six Walgreens retail pharmacies (collectively "Registrants") in 
Florida. The settlement further resolves open civil investigations in the District of Colorado, 
Eastern District of Michigan, and Eastern District of New York, as well as civil investigations by 
DEA field offices nationwide, pursuant to the Controlled Substances Act (the Act). 
 
 
April 3, 2013  CVS Pharmacy, Inc., and Oklahoma CVS Pharmacy, L.L.C., (collectively "CVS"), 
have agreed to pay $11,000,000 to the United States to settle civil penalty claims for record-
keeping violations under the Controlled Substances Act and related regulations, announced 
Administrator Michele M. Leonhart of the Drug Enforcement Administration (DEA) and Sanford 
C. Coats, United States Attorney for the Western District of Oklahoma. 
 
